MPLT
MapLight Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.77
+4.79%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -72.7%
- Operating cash flow
- -73.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +10.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -95.7%
- Free cash flow
- -74.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026